Shares of major private hospitals declined on September 30 after the Supreme Court criticized high markups on cancer drugs. The court suggested capping margins at 16% and questioned mandatory in-house pharmacy purchases, raising concerns among investors about potential impacts on hospital profitability.
Private hospital stocks faced a sharp decline in trading on September 30 after the Supreme Court of India raised concerns over aggressive pricing strategies for cancer medications. Shares of major hospital chains, including Apollo Hospitals, Max Healthcare, and Yatharth Hospital, saw their stock prices drop by 4% to 6% during the session as investors assessed the risk of stricter regulatory intervention in the healthcare sector.
The judicial bench, consisting of Justices Vikram Nath and Sandeep Mehta, expressed significant alarm over price discrepancies in oncology drugs. The court highlighted cases where medications sold to retailers for ₹2,700 were being billed to patients at an MRP of ₹27,000. Describing these markups as excessive, the court proposed a mandatory 16% profit margin cap on all pharmaceutical products. For investors, this development is critical because pharmacy services have become a major contributor to revenue and profitability for many large hospital chains in India. A regulatory cap on margins could directly pressure the profit margins that these hospitals have worked to build through their dedicated pharmacy arms.
Beyond the pricing of specific drugs, the court has also initiated a broader investigation into the hospital practice of forcing patients to purchase medicines exclusively from in-house pharmacies. This model, often referred to as captive consumption, limits patient choice and allows hospitals to control medicine distribution within their premises. The Supreme Court has directed the central government to examine these procurement mandates to ensure they do not stifle market competition or lead to predatory billing practices. Solicitor General Tushar Mehta, representing the government, acknowledged the court's observations and agreed that a regulatory balance is required to protect patient interests.
This judicial focus creates a new layer of uncertainty for the healthcare sector. Historically, private hospitals have expanded their pharmacy chains as part of a strategy to capture recurring revenue from patients undergoing treatment. If the government decides to amend the Drugs (Prices Control) Order, 2013, to enforce the suggested margin caps or restrict in-house pharmacy mandates, it could fundamentally alter the business models of large hospital operators. The market will now closely watch how the Ministry of Health responds to these observations and whether the government moves to translate these judicial suggestions into formal regulatory policies.